Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5183 - CD5 and CD6: evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Andrea Moreno

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

A. Moreno1, S. Calabuig Fariñas2, S. Gallach Garcia3, A. Fernando4, I. Simoes4, E. Carreras4, M. Consuegra-Fernández4, A. Blasco Cordellat5, A.J. Cunquero Tomas6, M. Martorell7, C. Camps8, F. Lozano9, R. Sirera Perez10, E. Jantus-Lewintre11

Author affiliations

  • 1 Molecular Oncology Laboratory, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 2 Molecular Oncology Laboratory, Fundación Investigación Hospital General Universitario Valencia - Ciberonc, Valencia, Spain, Pathology Department, Universitat de València, Valencia, Spain, 46018 - Valencia/ES
  • 3 Molecular Oncology Laboratory, Fundación de Investigación Hospital General Universitario de Valencia - CIBERONC, 46014 - Valencia/ES
  • 4 Immunoreceptors Of The Innate And Adaptative System, Institut d’Investigacions Biomèdiques August Pi i Sunyer, 08036 - Barcelona/ES
  • 5 Medical Oncology Service, Hospital General Universitario Valencia - CIBERONC, 46018 - Valencia/ES
  • 6 Medical Oncology Service, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 7 Pathology Service, Hospital General Universitario De Valencia, Valencia, Spain, Pathology Department, Universitat de València, 46014 - VALENCIA/ES
  • 8 Molecular Oncology Laboratory, Fundación Para La Investigación, Hospital General Universitario De Valencia-ciberonc, Valencia, Spain., Medical Oncology Service, Hospital General Universitario de Valencia - CIBERONC Valencia, Spain; Medicine Department, Universitat de València, Valencia, Spain, 46014 - Valencia/ES
  • 9 Immunoreceptors Of The Innate And Adaptative System, Institut D’investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain, Servei d’Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain; Departament de Biomedicina, Facultat de Medicina, Universitat de Barcelona, 08036 - Barcelona/ES
  • 10 Biotechnology Department, Universidad Politécnica de Valencia, 46005 - Valencia/ES
  • 11 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia-ciberonc, Valencia, Spain, Biotechnology Department, Universitat Politécnica de València, 46014 - Valencia/ES
More

Resources

Abstract 5183

Background

Non-Small Cell Lung Cancer (NSCLC) represents almost 80% of lung cancer cases. Despite the advances achieved in the last years, there is still a lack of knowledge concerning tumour microenvironment. This research is focused on two immunoregulatory genes, CD5 and CD6 as potential prognostic biomarkers in resectable NSCLC.

Methods

CD5 and CD6 gene expression was analysed by RTqPCR in 201 paired fresh-frozen tumour and normal tissue samples of resected NSCLC (training cohort). The Cancer Genome Atlas (TCGA) database was used to obtain an independent validation cohort with available gene expression data for normal and tumour tissue. Relative gene expression was calculated by Pfaffl formula. Prognostic value was assessed by Cox regression and Kaplan-Meier curves (log rank-test), considering significant p < 0.05.

Results

Training cohort consisted mainly of men, current or former smokers, with good performance status (PS = 0). Survival analyses showed that patients with higher CD5 expression had significantly increased overall survival (OS, 53.3 vs. NR months, p = 0.011). A multivariate analysis reported that CD5 expression could be established as an independent prognostic biomarker for OS in early-stage NSCLC [HR = 0.539; 95% CI, 0.329-0.883; p = 0.014]. Survival analyses performed on 97 patients from TCGA database confirmed that higher expression levels of both CD5 and CD6 had a significant prognostic value for relapse-free survival (34.98 vs. 75.57 months, p = 0.033; 25.31 vs. 75.57 months, p = 0.020, respectively) and OS (40.49 vs. 77.97 months, p = 0.038; 39.02 vs. 77.97 months, p = 0.034, respectively). Therefore, these analyses support that NSCLC patients with higher expression levels of CD5 are associated with better outcomes. Besides, CD6 could potentially be a prognostic biomarker.

Conclusions

Our results support a role of the inmmunodulatory receptor CD5 as an independent prognostic biomarker in resectable NSCLC. Supported from Fundació La Marató TV3 (201319-30), ISCIII (PI12-02838 and PI15-00753), and MECD (SAF2016-80535-R) -co-financed by European Development Regional Fund. FA and IS are recipients of fellowships from ISCIII (Sara Borrell Program; CD15/00016) and Portuguese FCT (SFRH/BD/75738/2011), respectively.

Clinical trial identification

Legal entity responsible for the study

Fundación para la Investigación del Hospital General Universitario de Valencia.

Funding

Supported from Fundació La Marató TV3 (201319-30), Instituto de Salud Carlos III (PI12-02838 and PI15-00753), and MECD (SAF2016-80535-R) -co-financed by European Development Regional Fund. FA and IS are recipients of fellowships from ISCIII (Sara Borrell Program; CD15/00016) and Portuguese Fundação para a Ciência e a Tecnologia (SFRH/BD/75738/2011), respectively.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings